Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04701086
Other study ID # RE-010-2020-SA
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 30, 2021
Est. completion date December 31, 2024

Study information

Verified date April 2024
Source Santen SAS
Contact Julia L Martin, BSc
Phone +447483081798
Email julia.martin@santen.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a prospective, multicentre, parallel-group, active-controlled, non-inferiority study conducted in adult patients with moderate-to-severe dry eye disease (DED) related to keratitis or keratoconjunctivitis. This study is to be conducted in France, Poland and Spain. The patients will be randomised to receive Cationorm Pro® or the reference treatment, VISMED® (ratio 1:1) in an investigator-masked fashion


Description:

Primary: • To compare the ocular efficacy of Cationorm Pro® with that of VISMED® in patients with moderate to severe DED related to keratitis or keratoconjunctivitis after a 4-week treatment period (Day 28). Secondary: To compare the ocular efficacy of Cationorm Pro® with that of VISMED® in patients with moderate to severe DED related to keratitis or keratoconjunctivitis over a 12-week treatment period To evaluate the ocular tolerability and safety of Cationorm Pro® versus VISMED® in patients with moderate to severe DED related to keratitis or keratoconjunctivitis throughout the duration of treatment


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date December 31, 2024
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Male or female patient aged 18 years or above. 2. Patient using artificial tears for at least 3 months prior to the Screening visit. 3. Patient experiencing at least 2 symptoms of ocular discomfort rated =23 mm on the 0 to 100 mm visual analogue scale (VAS) (among itching, eye dryness, sticky feeling, photophobia, pain, burning or stinging, sandy feeling or grittiness, or foreign body sensation) at Screening and Baseline visits. 4. OSS score (sum of nasal and temporal interpalpebral conjunctival and corneal vital staining) =4 and =9 on a modified Oxford scale at Screening and Baseline visits in at least one eye. 5. TBUT of =10 seconds at Screening and Baseline visits and/or Schirmer's tear test of =3 and =9 mm/5 min at Screening visit in the same eye that fulfil inclusion criteria #4. 6. The patient has signed and dated a written informed consent form prior to the initiation of any study procedures. - Exclusion Criteria: the study: Ocular 1. CFS score =4 on a modified Oxford scale 2. Ocular hypertension or glaucoma requiring IOP-lowering medication(s) 3. History of ocular trauma, infection or ocular inflammatory condition within the last 3 months before the screening visit. 4. Severe blepharitis and/or severe meibomian gland disease 5. Filamentary keratitis 6. Any ocular surface anomaly not related to DED 7. Active ocular infection or history of ocular allergy or ocular herpes 8. Patient with only one sighted eye or with a best corrected distance visual acuity =1/10 9. Use of any topical ocular treatment other than study device during the study (all non-study topical ocular treatment(s) must be stopped at the screening visit) 10. Onset of lid hygiene (whatever the method) less than 2 months before the Screening visit 11. Use of topical corticosteroids one month before the Screening Visit 12. Use of isotretinoin, ciclosporin, tacrolimus, sirolimus, pimecrolimus or ocular cauterisation procedures 2 months before the screening visit and throughout the study 13. Use of VISMED® within 6 weeks prior to the screening visit 14. Refractive surgery (e.g. LASIK, LASEK, PRK) within 6 months and/or any other ocular laser/surgery within 3 months prior to the screening visit and during the study 15. Insertion of temporary punctal plug(s) within 2 months prior to the Screening visit or permanent occlusion of lacrimal puncta on one or both sides 16. Known hypersensitivity to any of the components of the study device or investigational products Non-ocular 17. History of severe systemic allergy 18. Systemic disease not stabilised within 1 month prior to the screening visit (e.g. diabetes with glycaemia out of range, thyroid dysfunction) or judged by the investigator to be incompatible with the conduct of the study procedures or the interpretation of the study results 19. Any change of systemic concomitant medication within the month before the screening visit or planned change during the study period, except paracetamol 20. Pregnancy or lactation at the screening and/or Baseline visit. 21. Women of childbearing potential not using a medically acceptable, highly effective method of birth control (such as hormonal implants, injectable or oral contraceptives together with condoms, some intrauterine devices, sexual abstinence or vasectomised partner) from the Baseline visit throughout the conduct of the study treatment periods and up to 2 weeks after the study end. Post-menopausal women (two years without menstruation) do not need to use any method of birth control. 22. Participation in a clinical trial with an investigational substance within the past 30 days prior to Baseline visit. 23. Participation in another clinical study at the same time as the present study. -

Study Design


Intervention

Device:
Cationorm Pro
Eye Drops
Vismed
Eye Drops

Locations

Country Name City State
France Cabinet Liberal La Rochefoucauld
France CHRU Bretonneau Tours
Poland Gabinet Okulistyczny Bielsko-Biala
Poland Szpital SW. Rozy Krakow
Poland 5th MILITARY CLINICAL HOSPITAL IN KRAKOW Kraków
Poland Klinika Okulistyki i Onkologii Okulistycznej Kraków
Spain Centro de Oftalmologia Barraquer Barcelona
Spain Hospital Clinic of Barcelona Barcelona
Spain Hospital Unniversitario Donostia Donostia
Spain El Instituto Ofalmológico Quirónsalud Zaragoza Zaragoza

Sponsors (1)

Lead Sponsor Collaborator
Santen SAS

Countries where clinical trial is conducted

France,  Poland,  Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change of ocular surface staining (OSS) score between baseline and Day 28. The primary endpoint of the study is the difference between patients treated with Cationorm Pro® and patients treated with VISMED® in the change of ocular surface staining (OSS) score between baseline and D28.
An OSS higher than 0 is considered to be abnormal and may be a sign of KCS. But scores of 1 or 2 can also represent a late staining artifact if interpretation of the fluorescein corneal staining pattern is delayed beyond 8 minutes. Because this could lead to a high level of misclassification, an abnormal OSS is defined as being a score of 3 or above.
Between Baseline and day 28
Secondary Change of ocular surface staining (OSS) score between baseline and Day 84 The difference between patients treated with Cationorm Pro® and patients treated with VISMED® in change of OSS score between baseline and Day 84.
An OSS higher than 0 is considered to be abnormal and may be a sign of KCS. But scores of 1 or 2 can also represent a late staining artifact if interpretation of the fluorescein corneal staining pattern is delayed beyond 8 minutes. Because this could lead to a high level of misclassification, an abnormal OSS is defined as being a score of 3 or above.
between baseline and Day 14 and between baseline and Day 84
Secondary The change of ocular stainings (corneal fluorescein staining (CFS) and conjunctival staining) between baseline and Day 28 and between baseline and Day 84 The difference between patients treated with Cationorm Pro® and patients treated with VISMED® in change of ocular stainings (corneal fluorescein staining (CFS) and conjunctival staining)
Staining using fluorescein will be graded using the modified Oxford scale (7-point ordinal scale, score 0, 0.5, and 1 to 5 per area [cornea + nasal and temporal conjunctiva]) for cornea and conjunctiva separately, On this modified scale, the score 0 corresponds to no staining dots and the score 0.5 corresponds to one staining dot per area. A CFS grade of 0 represents complete corneal clearing.
between baseline and Day 28 and between baseline and Day 84
Secondary The change of ocular discomfort symptoms on Visual Analogue Scale The difference between patients treated with Cationorm Pro® and patients treated with VISMED® in the change of ocular discomfort symptoms according to the Visual Analogue Scale (VAS)
Patient experiencing at least 2 symptoms of ocular discomfort rated =23 mm on the 0 to 100 mm visual analogue scale (VAS) (among itching, eye dryness, sticky feeling, photophobia, pain, burning or stinging, sandy feeling or grittiness, or foreign body sensation) at Screening and Baseline visits.
between baseline and Day 28 and between baseline and Day 84
Secondary The change tear breakup time (TBUT) The difference between patients treated with Cationorm Pro® and patients treated with VISMED® in the change of tear breakup time (TBUT)
Generally, >10 seconds is thought to be normal,(10, 11, 12) 5 to 10 seconds, marginal, and < 5 seconds is considered low. A short tear break-up time is a sign of a poor tear film and the longer it takes the more stable the tear film.
between baseline and Day 28 and between baseline and Day 84
Secondary The change in Schirmer's tear test The difference between patients treated with Cationorm Pro® and patients treated with VISMED® in the change of Schirmer's tear test
Healthy eyes are considered to leave each strip of paper containing more than 10 millimeters of moisture. Less than 10 millimeters of moisture indicates probable dry eye syndrome
between baseline and Day 28 and between baseline and Day 84
Secondary The secondary endpoints are the difference between patients treated with Cationorm Pro® and patients treated with VISMED® in the change of overall efficacy evaluation of the investigator The study investigator at each centre will conduct an overall assessment of the effect of the study device on improvement in the patients DED using the following rating scale:
0 = Unsatisfactory
= Not very satisfactory
= Satisfactory
= Very satisfactory
after 12 weeks of treatment (84 days)
Secondary The difference between patients treated with Cationorm Pro® and patients treated with VISMED® in the change of subjective assessments evaluation by the patient. The patient will rate his global evaluation of efficacy using the same rating scale as the Investigator.
A subjective assessment is completed of the effect of the study device on improvement in their DED using the following rating scale:
0 = Unsatisfactory
= Not very satisfactory
= Satisfactory
= Very satisfactory
between baseline and Day 84
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04425551 - Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction N/A
Not yet recruiting NCT06379685 - Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface. Phase 1
Active, not recruiting NCT03697876 - Safety and Tolerability of the Ophthalmic Gel PRO-165 Versus Artelac® Nightime Gel Phase 1
Completed NCT02910713 - Evaluation of Dry Eye Symptoms in CAE With Application of Intranasal Neurostimulation N/A
Terminated NCT02815293 - Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye Phase 3
Completed NCT04104997 - A Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of GLH8NDE After Single and Mutiple Ocular Administrations in Healthy Korean and Caucasian Volunteers Phase 1
Recruiting NCT02595606 - 0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients Phase 4
Completed NCT01711424 - An Observational Study of OPTIVE PLUS® for the Treatment of Dry Eye Disease N/A
Completed NCT01202747 - Evaluation of Screening Methods for Treatment of Meibomian Gland Dysfunction Phase 2/Phase 3
Completed NCT01015209 - Safety and Tolerability of Chitosan-N-acetylcysteine Eye Drops in Healthy Young Volunteers Phase 1
Completed NCT00969280 - Acupuncture for Dry Eye Syndrome Phase 3
Completed NCT00739713 - Effects of Sea Buckthorn Oil on Dry Eye N/A
Completed NCT00756678 - Efficacy and Acceptability of Two Lubricant Eye Drops Phase 4
Completed NCT01496482 - Comparison of Evaporimetry With the Established Methods of Tear Film Measurement N/A
Completed NCT00370747 - Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome Phase 2
Completed NCT00349440 - Efficacy of Cyclosporine for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy Phase 4
Completed NCT05162261 - to Evaluate the Effectiveness and Safety of the Tixel® , VS LipiFlow® in the Treatment of Meibomian Gland Dysfunction N/A
Completed NCT02871440 - A Two Comparator, Controlled Phase 3 Study in Patients With and Without Evaporative Dry Eye Phase 3
Completed NCT05042960 - Computer Screen Properties Study N/A
Not yet recruiting NCT05990712 - The Effect of a Pre-cataract Surgical Ocular Hygiene Regime on Microbial Load, Tear Osmolarity, Dry Eye, and Inflammatory Markers Phase 4